References
- Bauernfeind A. Comparative in vitro activities of the new quinolone, Bay y3118, and ciprofloxacin, sparfloxacin, tesufloxacin, CI- 960 and CI-990. J Antiraicrob Chemother, 1993; 31: 505–522.
- Davies S, Sparham PD, Spencer RC. Comparative in vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother, 1987; 19: 605–609.
- King A, Phillips I. The comparative in vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother, 1986; 18, suppl. D: 1–20.
- Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev, 1989; 2: 378–424.
- Bremm KD, Petersen U, Metzger KG, Endernam R. In vitro evaluation of Bay y3118, a new full-spectrum fluoroquinolone. Chemotherapy, 1992; 38: 376–387.
- Nord CE, Lindmark A, Persson I. In vitro activity of the new quinolone Bay y3118 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis, 1993; 12: 640–642.
- Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibility of 428 Gram-positive and negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam and cefoxitin. Antimicrob Agents Chemother, 1993; 37: 1649–1654.
- Spangler SK, Jacobs MR, Appelbaum PC. Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci. Eur J Clin Microbiol Infect Dis, 1993; 12: 965–967.
- National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Second Edition. Approved Standard M7-A2. National Committee for Clinical Laboratory Standards Villanova, PA, 1990.
- Pirali F, Colombrita D, Gelmi M et al. Rapid methods for microbial diagnosis of mycobacterial infections. Microbiology 1993; 16: 245–250.